Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BridgeBio Pharma (BBIO) Return on Capital Employed (2019 - 2025)

BridgeBio Pharma (BBIO) has disclosed Return on Capital Employed for 7 consecutive years, with 0.77% as the latest value for Q4 2025.

  • Quarterly Return on Capital Employed rose 16.0% to 0.77% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.77% through Dec 2025, up 16.0% year-over-year, with the annual reading at 0.82% for FY2025, 21.0% up from the prior year.
  • Return on Capital Employed hit 0.77% in Q4 2025 for BridgeBio Pharma, down from 0.74% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.53% in Q2 2021 to a low of 1.33% in Q4 2023.
  • Historically, Return on Capital Employed has averaged 0.86% across 5 years, with a median of 0.82% in 2022.
  • Biggest five-year swings in Return on Capital Employed: crashed -41bps in 2023 and later skyrocketed 43bps in 2024.
  • Year by year, Return on Capital Employed stood at 0.76% in 2021, then dropped by -22bps to 0.92% in 2022, then crashed by -44bps to 1.33% in 2023, then soared by 30bps to 0.93% in 2024, then rose by 17bps to 0.77% in 2025.
  • Business Quant data shows Return on Capital Employed for BBIO at 0.77% in Q4 2025, 0.74% in Q3 2025, and 0.82% in Q2 2025.